聖湘生物(688289.SH):腺病毒核酸檢測試劑盒(PCR-熒光探針法)取得醫療器械註冊證
格隆匯3月8日丨聖湘生物(688289.SH)公佈,公司的產品腺病毒核酸檢測試劑盒(PCR-熒光探針法)於近日收到由國家藥品監督管理局頒發的《醫療器械註冊證》。
腺病毒核酸檢測試劑盒(PCR-熒光探針法)可用於對人腺病毒呼吸道感染的診斷,為腺病毒感染提供分子診斷依據,檢測結果可指導腺病毒疫情調查、預防控制和病例管理等工作,應用場景覆蓋門診、ICU、體檢等。該產品的推出將為呼吸道感染提供更全面可及的一體化服務解決方案,提高呼吸道病原體檢測的“精確性”和“可及性”,推動以預防為主的健康策略和早診早治的精準診療體系建設。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.